the sun malaysia ipaper logo 150x150
Friday, July 3, 2026
28.6 C
Kuala Lumpur
the sun malaysia ipaper logo 150x150

HRD Corp: MACC forms special investigation team

KUALA LUMPUR: The Malaysian Anti-Corruption Commission (MACC) has formed a special investigation team to scrutinise the documents provided by the Ministry of Human Resources (KESUMA) regarding issues involving the Human Resource Development Corporation (HRD Corp).

In a statement today, deputy chief commissioner (Operations) Datuk Seri Ahmad Khusairi Yahaya stated that the information and documents related to the Auditor General’s Report on HRD Corp, received from KESUMA’s secretary-general Datuk Seri Khairul Dzaimee Daud, have been reviewed.

“Based on the audit report, we have identified several issues that require documentation and testimony from the involved parties, among others on matters of investment, fund management and training, as well as property acquisition.

“Therefore, a special team has been formed, and several investigation papers have been initiated. On Tuesday (July 9), the investigation team will visit KESUMA and HRD Corp to obtain additional documents,“ he said.

He added that several individuals have been identified to provide statements to assist the investigation, which will be conducted under the MACC Act 2009, particularly under Sections 18 and 23.

Yesterday, the MACC confirmed receiving information and several documents on HRD Corp related to the Auditor General’s Report from Khairul Dzaimee.

Following this, MACC is examining the entire set of documents to determine whether there are any elements of corruption, misappropriation, or abuse of power under the MACC Act 2009.

STAY AHEAD OF THE CURVE

Join our community for instant updates and exclusive content.

Join Telegram Channel

Related


spot_img

Latest News

Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Manufacturing Operations

TAIPEI, TAIWAN - Media OutReach Newswire - 2 July 2026 - Bora Pharmaceuticals Co., Ltd. ("Bora" or "Bora Group"; TWSE: 6472; OTCQX: BORAY) today announced the completion of its acquisition of the GMP manufacturing operations of MacroGenics, Inc. (NASDAQ: MGNX) including its biologics drug substance facility in Rockville, Maryland and an associated warehousing center in Frederick, Maryland, for total consideration of US $122.5 million through its wholly owned subsidiary Bora Biologics USA, LLC.. Upon closing, Bora signed a long-term CDMO Service Agreement with MacroGenics.

Most Viewed

spot_img
WC26

World Cup 2026

Updates, Fixtures, Results & Standings